CA3253847A1 - HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE - Google Patents

HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE

Info

Publication number
CA3253847A1
CA3253847A1 CA3253847A CA3253847A CA3253847A1 CA 3253847 A1 CA3253847 A1 CA 3253847A1 CA 3253847 A CA3253847 A CA 3253847A CA 3253847 A CA3253847 A CA 3253847A CA 3253847 A1 CA3253847 A1 CA 3253847A1
Authority
CA
Canada
Prior art keywords
heterocyclyl
alkyl
group
cycloalkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253847A
Other languages
English (en)
French (fr)
Inventor
Xin Li
Bin Wang
Huaide DONG
Feng He
Weikang Tao
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3253847A1 publication Critical patent/CA3253847A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3253847A 2022-03-28 2023-03-28 HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE Pending CA3253847A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202210330007 2022-03-28
CN202210330007.4 2022-03-28
CN202210944231.2 2022-08-05
CN202210944231 2022-08-05
CN202211255163.5 2022-10-13
CN202211255163 2022-10-13
PCT/CN2023/084265 WO2023185793A1 (zh) 2022-03-28 2023-03-28 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CA3253847A1 true CA3253847A1 (en) 2025-07-04

Family

ID=88199144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253847A Pending CA3253847A1 (en) 2022-03-28 2023-03-28 HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE

Country Status (10)

Country Link
US (1) US20250206760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4501925A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509995A (cg-RX-API-DMAC7.html)
KR (1) KR20240167844A (cg-RX-API-DMAC7.html)
CN (1) CN118715216A (cg-RX-API-DMAC7.html)
AU (1) AU2023243776A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253847A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011705A (cg-RX-API-DMAC7.html)
TW (1) TW202345816A (cg-RX-API-DMAC7.html)
WO (1) WO2023185793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4786473A1 (en) * 2023-09-27 2026-08-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof
TW202530232A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的結晶形式及其製備方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN115057861A (zh) 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲(江蘇)醫藥股份有限公司 ErbB受體抑制劑
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
US20230126204A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN115052881B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
CA3175102A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. Erbb receptor inhibitors as anti-tumor agents
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN115697994B (zh) 2020-06-10 2024-08-13 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
US20240398805A1 (en) * 2021-02-05 2024-12-05 Accutar Biotechnology Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
EP4476211A4 (en) * 2022-02-09 2026-02-25 Enliven Inc ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS

Also Published As

Publication number Publication date
MX2024011705A (es) 2024-11-08
EP4501925A1 (en) 2025-02-05
KR20240167844A (ko) 2024-11-28
AU2023243776A1 (en) 2024-09-12
US20250206760A1 (en) 2025-06-26
CN118715216A (zh) 2024-09-27
JP2025509995A (ja) 2025-04-11
WO2023185793A1 (zh) 2023-10-05
TW202345816A (zh) 2023-12-01
EP4501925A4 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
JP7502365B2 (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
EP3564232B1 (en) Bmp-signal-inhibiting compound
KR100548853B1 (ko) 아졸로 트리아진 및 피리미딘
EP2143724B1 (en) Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
KR20150108389A (ko) 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법
JP2021516242A (ja) 置換1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン
EP4501925A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
KR101664460B1 (ko) 디하이드로피리다진-3,5-디온 유도체
CA2838784A1 (en) Pyrazolo[3,4-c]pyridine compounds and methods of use
EP3556761B1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
MX2014008201A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso.
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
WO2023192416A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
EP3894401A2 (en) Naphthyridine and quinoline derivatives useful as alk5 inhibitors
EA032643B1 (ru) Имидазопиридазиновые соединения в качестве ингибиторов pik
WO2024211346A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
US20020147338A1 (en) Pyrazolotriazines as CRF antagonists
CN119855817B (zh) 杂环炔基取代的酰胺衍生物、其制备方法及其应用
KR20170047388A (ko) 나트륨 의존성 인산 트랜스포터 저해제를 함유하는 의약
JP2022532145A (ja) 置換ベンズイミダゾロン化合物
US20200055852A1 (en) Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
WO2024086789A2 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
CN117903172A (zh) 取代的含氮杂芳基类化合物、其制备方法及其在医药上的应用
EP3917929A1 (en) The monohydrate of rogaratinib hydrochloride and solid states thereof
EA052991B1 (ru) Азотсодержащее гетероциклическое соединение, способ его получения и его фармацевтическое применение

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240830

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250122

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250122

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250131

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202